GLP-1 receptor agonists at the crossroads of diabetes, hepatic steatosis, and hepatocellular carcinoma
Internal and Emergency Medicine · 2026-10 · 21 (7) · 2443-2465
DOI: 10.1007/s11739-026-04456-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Internal and Emergency Medicine, online erschienen am 28.07.2026. Verfasst von Alfredo Vozza und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Medicina Sperimentale e Clinica, University of Florence, Largo Brambilla, 3, 50134, Florence, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Firenze.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The epidemiology of hepatocellular carcinoma (HCC) is increasingly shaped by the expanding burden of type 2 diabetes (T2D), obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD). Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed as glucose-lowering agents, have emerged as systemic metabolic therapies with effects extending beyond glycemic control, including weight reduction, cardiovascular and renal protection, and improvement of steatotic liver disease. This review summarizes current evidence on the potential role of GLP-1RAs in modifying the natural history of MASLD and reducing HCC risk. Clinical trials consistently support beneficial effects on steatosis and metabolic dysfunction-associated steatohepatitis, particularly in non-cirrhotic patients, whereas effects in established cirrhosis appear less consistent. Real-world studies and target trial emulations suggest that GLP-1RA use may be associated with lower rates of hepatic decompensation, cirrhosis progression, and incident HCC, although the magnitude and robustness of these associations vary according to disease stage, comparator therapy, exposure definition, and outcome hierarchy. The strongest apparent benefit is generally observed against insulin or sulfonylureas, while differences are attenuated in comparisons with other metabolically favorable agents, such as SGLT2 inhibitors. Mechanistic data support indirect hepatoprotective actions mediated by reduced insulin resistance, lipotoxicity, inflammation, fibrogenesis, adipose–liver crosstalk, and tumor-promoting pathways. Overall, GLP-1RAs represent promising disease-modifying agents in metabolic liver disease, but dedicated prospective studies are required to establish causality and define their role in HCC prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Medicina Sperimentale e Clinica, University of Florence, Largo Brambilla, 3, 50134, Florence, Italy.
- Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy.
- Internal Medicine Unit, SS. Annunziata Hospital, Taranto, Italy.
- Dipartimento di Medicina Sperimentale e Clinica, University of Florence, Largo Brambilla, 3, 50134, Florence, Italy. fabio.marra@unifi.it.
Förderung
- Università degli Studi di Firenze
Zitieren
APA
Vozza, A., Biagi, F., Raggi, C., Vizzutti, F., & Marra, F. (2026). GLP-1 receptor agonists at the crossroads of diabetes, hepatic steatosis, and hepatocellular carcinoma. Internal and Emergency Medicine, 21(7), 2443-2465. https://doi.org/10.1007/s11739-026-04456-1
Vancouver
Vozza A, Biagi F, Raggi C, Vizzutti F, Marra F. GLP-1 receptor agonists at the crossroads of diabetes, hepatic steatosis, and hepatocellular carcinoma. Internal and Emergency Medicine. 2026;21(7):2443-2465. doi:10.1007/s11739-026-04456-1
BibTeX
@article{Vozza2026,
author = {Vozza, Alfredo and Biagi, Filippo and Raggi, Chiara and Vizzutti, Francesco and Marra, Fabio},
title = {GLP-1 receptor agonists at the crossroads of diabetes, hepatic steatosis, and hepatocellular carcinoma},
journal = {Internal and Emergency Medicine},
year = {2026},
volume = {21},
number = {7},
pages = {2443--2465},
doi = {10.1007/s11739-026-04456-1}
}
EUVIMED